Two Sigma Investments
INBX

Two Sigma Investments’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Two Sigma Investments’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-78,400
Closed -$2.74M – 3470
2024
Q1 		$2.74M Buy
78,400
+70,500
+892% +$2.57M 0.01% 1278
2023
Q4 		$300K Sell
7,900
-199,770
-96% -$4.28M ﹤0.01% 2697
2023
Q3 		$3.81M Sell
207,670
-52,750
-20% -$1.1M 0.01% 1038
2023
Q2 		$6.76M Sell
260,420
-75,383
-22% -$1.76M 0.02% 809
2023
Q1 		$6.34M Buy
335,803
+89,802
+37% +$2.09M 0.02% 797
2022
Q4 		$6.06M Buy
246,001
+82,512
+50% +$2.43M 0.02% 772
2022
Q3 		$2.94M Buy
163,489
+39,264
+32% +$708K 0.01% 979
2022
Q2 		$1.41M Buy
124,225
+66,452
+115% +$978K ﹤0.01% 1379
2022
Q1 		$1.29M Buy
+57,773
New +$1.47M ﹤0.01% 1576
2021
Q2 		– Sell
-17,688
Closed -$355K – 4835
2021
Q1 		$355K Buy
+17,688
New +$516K ﹤0.01% 3208

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Investments's INBX Position: Q2 2024 in Review

Two Sigma Investments sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 78,400 shares — an estimated $2.74M sold.

Two Sigma Investments first reported a position in INBX in Q1 2021 and held it in 10 quarters. The position peaked at $6.76M in Q2 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Two Sigma Investments reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Investments sold 78,400 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $2.74M.
  • Two Sigma Investments first reported a position in Inhibrx, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • Two Sigma Investments's Inhibrx, Inc. Common Stock position peaked at $6.76M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.